JP2006520343A - ２−（ブチル−１−スルホニルアミノ）−ｎ−［１（ｒ）−（６−メトキシピリジン−３−イル）プロピル］ベンズアミド、医薬としてのその使用及び該化合物を含有する医薬製剤 - Google Patents

２−（ブチル−１−スルホニルアミノ）−ｎ−［１（ｒ）−（６−メトキシピリジン−３−イル）プロピル］ベンズアミド、医薬としてのその使用及び該化合物を含有する医薬製剤 Download PDF

Info

Publication number
JP2006520343A
JP2006520343A JP2006504553A JP2006504553A JP2006520343A JP 2006520343 A JP2006520343 A JP 2006520343A JP 2006504553 A JP2006504553 A JP 2006504553A JP 2006504553 A JP2006504553 A JP 2006504553A JP 2006520343 A JP2006520343 A JP 2006520343A
Authority
JP
Japan
Prior art keywords
methoxypyridin
sulfonylamino
butyl
benzamide
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006504553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520343A5 (https=
Inventor
ヨーアヒム・ブレンデル
ハインツ・ゲーゲライン
クラウス・ヴィルト
ゲルト・ウルリッヒ・キュルツェル
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2006520343A publication Critical patent/JP2006520343A/ja
Publication of JP2006520343A5 publication Critical patent/JP2006520343A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2006504553A 2003-03-18 2004-03-05 ２−（ブチル−１−スルホニルアミノ）−ｎ−［１（ｒ）−（６−メトキシピリジン−３−イル）プロピル］ベンズアミド、医薬としてのその使用及び該化合物を含有する医薬製剤 Abandoned JP2006520343A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (de) 2003-03-18 2003-03-18 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen
PCT/EP2004/002247 WO2004083157A1 (de) 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, dessen verwendung als medikament sowie dieses enthaltende pharmazeutische zubereitungen

Publications (2)

Publication Number Publication Date
JP2006520343A true JP2006520343A (ja) 2006-09-07
JP2006520343A5 JP2006520343A5 (https=) 2007-04-19

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504553A Abandoned JP2006520343A (ja) 2003-03-18 2004-03-05 ２−（ブチル−１−スルホニルアミノ）−ｎ−［１（ｒ）−（６−メトキシピリジン−３−イル）プロピル］ベンズアミド、医薬としてのその使用及び該化合物を含有する医薬製剤

Country Status (21)

Country Link
EP (1) EP1606237A1 (https=)
JP (1) JP2006520343A (https=)
KR (1) KR20050110681A (https=)
CN (1) CN100361943C (https=)
AR (1) AR043622A1 (https=)
AU (1) AU2004222137A1 (https=)
BR (1) BRPI0408441A (https=)
CA (1) CA2519022A1 (https=)
DE (1) DE10312073A1 (https=)
HR (1) HRP20050815A2 (https=)
MA (1) MA27749A1 (https=)
MX (1) MXPA05009763A (https=)
MY (1) MY176510A (https=)
NO (1) NO20054472L (https=)
NZ (1) NZ542476A (https=)
PE (1) PE20050307A1 (https=)
RS (1) RS20050690A (https=)
RU (1) RU2333202C2 (https=)
TW (1) TW200500342A (https=)
WO (1) WO2004083157A1 (https=)
ZA (1) ZA200506328B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528078A (ja) * 2009-05-29 2012-11-12 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
WO2007015775A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472053B1 (en) * 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528078A (ja) * 2009-05-29 2012-11-12 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
US9522140B2 (en) 2009-05-29 2016-12-20 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Also Published As

Publication number Publication date
PE20050307A1 (es) 2005-06-08
DE10312073A1 (de) 2004-09-30
TW200500342A (en) 2005-01-01
HK1086819A1 (en) 2006-09-29
RU2005132163A (ru) 2006-04-10
RS20050690A (sr) 2008-04-04
MY176510A (en) 2020-08-12
WO2004083157A1 (de) 2004-09-30
RU2333202C2 (ru) 2008-09-10
ZA200506328B (en) 2006-04-26
MA27749A1 (fr) 2006-02-01
MXPA05009763A (es) 2006-01-27
CN100361943C (zh) 2008-01-16
BRPI0408441A (pt) 2006-04-04
NZ542476A (en) 2008-05-30
CN1756728A (zh) 2006-04-05
AU2004222137A1 (en) 2004-09-30
KR20050110681A (ko) 2005-11-23
AR043622A1 (es) 2005-08-03
NO20054472L (no) 2005-09-27
CA2519022A1 (en) 2004-09-30
HRP20050815A2 (en) 2006-09-30
EP1606237A1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
JP2016145261A (ja) 疾患を治療するための医薬品
JP2007077162A (ja) アミノシクロヘキシルエーテル化合物およびそれらの用途
JP2006525227A5 (https=)
KR100939243B1 (ko) 포타슘 채널의 기능을 조절하는 아민 유도체, 그의제조방법 및 용도
TW202131924A (zh) 以ｒｖｘ－２０８及ｓｇｌｔ２抑制劑治療及／或預防主要不良心血管事件（ｍａｃｅ）的方法
JP2006520343A (ja) ２−（ブチル−１−スルホニルアミノ）−ｎ−［１（ｒ）−（６−メトキシピリジン−３−イル）プロピル］ベンズアミド、医薬としてのその使用及び該化合物を含有する医薬製剤
JP4658919B2 (ja) フェニルカルボン酸アミドおよびＩＫｒチャンネル遮断剤の組み合わせならびに心房性不整脈を処置するためのその使用
JP2022537518A (ja) 脳神経または心臓保護剤としてのアミノチオール系化合物の使用
JP5849336B2 (ja) アデニル酸シクラーゼの活性調節剤
JP5960695B2 (ja) パンテニルドコサヘキサエノアート、ならびに心血管疾患を治療および予防するためのその使用
Plouvier et al. Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation
JP2002504134A (ja) 疼痛を治療するためのドラフラジン類似体の使用
JP2003506356A (ja) 神経学的疾患の治療のための環状アミン誘導体
US20050054673A1 (en) Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
JP2800830B2 (ja) １，２，３，４−テトラヒドロイソキノリン抗不整脈薬
US20080081926A1 (en) Sulfonylaminobenzoic acid and salt
JP5583325B2 (ja) イオンチャネル調節化合物の投与レジメ
JP2007523926A (ja) 心房収縮性の選択的増加及び心不全の治療のためのＫｖ１．５遮断剤
JP2007505036A (ja) フェニルカルボキサミドとβ−アドレナリン性受容体遮断剤の組み合わせおよびそれらの心房性不整脈の処置のための使用
JP2003503484A (ja) アミノアルキル誘導体
HK1086819B (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]- benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
JP2003503478A (ja) 神経学的疾患の治療のためのβ−アミノ酸誘導体
JPH0149707B2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070223

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20091201